Scholarlink

<p>Programmed cell death 1 (PD-1) is a CD28/CTLA-4 family member of immune checkpoint inhibitors. A lot of it is also made up of T cells worn out from being around tumors, which weakens the immune system. PD-1 binds to a protein called PD-L1, which stops T cells from fighting cancer. Inhibitors of the PD-1/PD-L1 pathway have changed how cancer is handled and have shown much potential against several types of cancer. However, there have been many accounts of bad things happening with the circulatory system in cancer patients who were being treated with anti-PD-1/PD-L1. To address these issues, it has been essential to develop alternative therapeutic approaches. Using small interfering RNA (siRNAs) to target immune checkpoint molecules can activate immune cells and prevent tumor cells from suppressing these activated immune cells. However, due to the highly charged nucleic acid backbone, making safe and effective tools for delivering these molecules only to tumor cells is a necessary first step toward their future use as medicines. Using secure, biodegradable nanocarriers to give these medicines to their intended locations will improve the treatment. In this study, we discussed the importance of PD-L1 siRNA in treating various types of cancer. Finally, we discussed the problems with this method and examined the new process that can address these issues. This review aims to spark researchers’ interest in enhancing PD-L1 siRNA’s efficacy against cancer and addressing its therapeutic limitations.</p> Graphical abstract <p>By inhibiting the expression of PD-L1, a protein that aids cancer cells in eluding the immune system, PD-L1 siRNA nanoparticles provide a potential strategy in cancer treatment. <i>AGO2</i> Argonaute 2, <i>mRNAs</i> messenger RNAs, <i>NPs</i> nanoparticles, <i>PD-L1</i> programmed death-ligand 1, <i>siRNAs</i> small interfering RNA<b>.</b></p> <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Targeting tumor immune evasion: the role of PD-L1 siRNA in advancing cancer immunotherapy

  • 期刊论文

  • 发表日期：

    2025年9月13日

查看全文
  • Shahad Mohammed Dhiaa Younis,
  • Abdulkareem Shareef,
  • Ashok Kumar Bishoyi,
  • Rami Oweis,
  • H. Malathi,
  • Arshdeep Singh,
  • Samir Sahoo,
  • Ashish Singh Chauhan,
  • Hayder Naji Sameer,
  • Ahmed Yaseen,
  • Zainab H. Athab,
  • Mohaned Adil

摘要

Programmed cell death 1 (PD-1) is a CD28/CTLA-4 family member of immune checkpoint inhibitors. A lot of it is also made up of T cells worn out from being around tumors, which weakens the immune system. PD-1 binds to a protein called PD-L1, which stops T cells from fighting cancer. Inhibitors of the PD-1/PD-L1 pathway have changed how cancer is handled and have shown much potential against several types of cancer. However, there have been many accounts of bad things happening with the circulatory system in cancer patients who were being treated with anti-PD-1/PD-L1. To address these issues, it has been essential to develop alternative therapeutic approaches. Using small interfering RNA (siRNAs) to target immune checkpoint molecules can activate immune cells and prevent tumor cells from suppressing these activated immune cells. However, due to the highly charged nucleic acid backbone, making safe and effective tools for delivering these molecules only to tumor cells is a necessary first step toward their future use as medicines. Using secure, biodegradable nanocarriers to give these medicines to their intended locations will improve the treatment. In this study, we discussed the importance of PD-L1 siRNA in treating various types of cancer. Finally, we discussed the problems with this method and examined the new process that can address these issues. This review aims to spark researchers’ interest in enhancing PD-L1 siRNA’s efficacy against cancer and addressing its therapeutic limitations.

Graphical abstract

By inhibiting the expression of PD-L1, a protein that aids cancer cells in eluding the immune system, PD-L1 siRNA nanoparticles provide a potential strategy in cancer treatment. AGO2 Argonaute 2, mRNAs messenger RNAs, NPs nanoparticles, PD-L1 programmed death-ligand 1, siRNAs small interfering RNA.